Opendata, web and dolomites

IMMUNOMARK SIGNED

Omics integration for precision cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNOMARK project word cloud

Explore the words cloud of the IMMUNOMARK project. It provides you a very rough idea of what is the project "IMMUNOMARK" about.

tumor    liquid    wp2    l1    prevent    sorted    2020    line    detection    pd    treatment    disease    transcriptomics    elucidate    anti    solid    cd56    genes    samples    cohort    cd8    integrative    amenable    immunotherapies    treat    checkpoint    detect    definitive    immunologic    revolution    monitor    identification    clinical    wp1    post    epigenetic    metastatic    provides    validation    urgent    ctla4    circulating    biological    melanoma    30    mapping    differentially    proteins    innovation    biopsies    marks    genetic    inhibitors    multiple    fac    era    parts    omics    signature    immunotherapy    tested    followed    innovative    patients    lung    agents    genome    biomarkers    structure    biopsy    lack    therapy    linked    health    cancer    applies    invasively    cells    outcome    blood    small    horizon    expressed    methylation    limited    responders    multilayer    beginning    tissues    stroma    definite    total    integrating    rational    cell    predictive   

Project "IMMUNOMARK" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD 

Organization address
address: CALLE DOCTOR MIGUEL DIAZ RECIO 28 PLANTA BAJA
city: MALAGA
postcode: 29010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD ES (MALAGA) coordinator 170˙121.00

Map

 Project objective

The development of immunotherapies based on checkpoint inhibitors marks the beginning of a new era in the treatment of cancer, with 20-30% of tumor response in advanced non–small-cell lung cancer and melanoma. However, the rational use of these agents has been limited by the lack of definitive predictive biomarkers. The recent “omics revolution” provides great opportunities to elucidate the biological processes linked to the treatment outcome. Here we propose a multilayer integrative omics analysis using transcriptomics and genetic and epigenetic mapping, together with detection of specific immunologic proteins, to identify biomarkers of clinical response to immunotherapy amenable to be used in liquid biopsies. Objective: to identify definite biomarkers predictive of the response to anti-PD-1, anti-PD-L1, and anti-CTLA4 therapy in patients with metastatic melanoma and advanced non–small-cell lung cancer. We structure the proposal in two parts: WP1. Signature of response to the immunotherapy by integrating transcriptomics and genetic and epigenetic mapping in tumor tissues: solid biopsy. Genome-wide transcriptomics on FAC-sorted tumor and stroma cells followed by targeted genetic and epigenetic mapping in the differentially expressed genes in responders. WP2: Identification of circulating biomarkers of response to the immunotherapy: liquid biopsy. Pre- and post-treatment blood samples from a validation cohort will be used as liquid biopsy. Genetic and epigenetic biomarkers of WP1 will be tested as circulating biomarkers. In addition, LINE-1 methylation, total Circulating Tumor Cells, CD56, or CD8 PD-1 cells will be tested. This project applies multiple innovative approaches to address the urgent need of identifying biomarkers of clinical response to immunotherapy in cancer, amenable to be used non-invasively. In line with the Horizon 2020 Research & Innovation goal, we will “improve our ability to monitor health and to prevent, detect, treat and manage disease.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

POMOC (2019)

Charles IV and the power of marvellous objects

Read More  

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More